Bactiguard Holding AB (publ) (BACTI-B.ST)
SEK 37.2
(-2.11%)
SEK 37.2
(-2.11%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 682.87 Million SEK | -15.45% |
| 2022 | 807.7 Million SEK | -4.9% |
| 2021 | 849.28 Million SEK | 25.78% |
| 2020 | 675.22 Million SEK | 5.28% |
| 2019 | 641.36 Million SEK | 9.17% |
| 2018 | 587.47 Million SEK | -6.06% |
| 2017 | 625.39 Million SEK | -1.06% |
| 2016 | 632.07 Million SEK | -6.53% |
| 2015 | 676.24 Million SEK | -16.63% |
| 2014 | 811.12 Million SEK | 13.09% |
| 2013 | 717.23 Million SEK | 1.93% |
| 2012 | 703.63 Million SEK | 8.13% |
| 2011 | 650.73 Million SEK | 20.54% |
| 2010 | 539.84 Million SEK | -12.84% |
| 2009 | 619.35 Million SEK | -10.27% |
| 2008 | 690.26 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 669.42 Million SEK | -1.97% |
| 2024 Q3 | 676.15 Million SEK | -0.17% |
| 2024 Q2 | 677.33 Million SEK | 1.18% |
| 2023 Q3 | 699.68 Million SEK | -4.69% |
| 2023 FY | 682.87 Million SEK | -15.45% |
| 2023 Q1 | 785.52 Million SEK | -2.75% |
| 2023 Q2 | 734.1 Million SEK | -6.55% |
| 2023 Q4 | 682.87 Million SEK | -2.4% |
| 2022 Q3 | 825.77 Million SEK | -0.4% |
| 2022 FY | 807.7 Million SEK | -4.9% |
| 2022 Q1 | 840.75 Million SEK | -1.0% |
| 2022 Q4 | 807.7 Million SEK | -2.19% |
| 2022 Q2 | 829.11 Million SEK | -1.38% |
| 2021 Q2 | 666.79 Million SEK | -0.62% |
| 2021 Q3 | 864.52 Million SEK | 29.65% |
| 2021 Q4 | 849.28 Million SEK | -1.76% |
| 2021 FY | 849.28 Million SEK | 25.78% |
| 2021 Q1 | 670.96 Million SEK | -0.63% |
| 2020 Q2 | 707.41 Million SEK | -3.68% |
| 2020 Q1 | 734.43 Million SEK | 14.51% |
| 2020 Q3 | 698.47 Million SEK | -1.26% |
| 2020 Q4 | 675.22 Million SEK | -3.33% |
| 2020 FY | 675.22 Million SEK | 5.28% |
| 2019 Q2 | 645.6 Million SEK | -1.59% |
| 2019 Q1 | 656.03 Million SEK | 11.67% |
| 2019 Q3 | 657.22 Million SEK | 1.8% |
| 2019 Q4 | 641.36 Million SEK | -2.41% |
| 2019 FY | 641.36 Million SEK | 9.17% |
| 2018 Q3 | 600.08 Million SEK | -1.51% |
| 2018 Q2 | 609.26 Million SEK | -1.79% |
| 2018 Q1 | 620.35 Million SEK | -0.81% |
| 2018 FY | 587.47 Million SEK | -6.06% |
| 2018 Q4 | 587.47 Million SEK | -2.1% |
| 2017 Q4 | 625.39 Million SEK | -1.42% |
| 2017 Q2 | 640.67 Million SEK | -1.25% |
| 2017 Q1 | 648.79 Million SEK | 2.65% |
| 2017 FY | 625.39 Million SEK | -1.06% |
| 2017 Q3 | 634.41 Million SEK | -0.98% |
| 2016 FY | 632.07 Million SEK | -6.53% |
| 2016 Q4 | 632.07 Million SEK | -3.73% |
| 2016 Q3 | 656.53 Million SEK | 0.05% |
| 2016 Q2 | 656.19 Million SEK | -1.69% |
| 2016 Q1 | 667.45 Million SEK | -1.3% |
| 2015 FY | 676.24 Million SEK | -16.63% |
| 2015 Q4 | 676.24 Million SEK | -5.12% |
| 2015 Q3 | 712.75 Million SEK | -4.33% |
| 2015 Q2 | 744.98 Million SEK | -2.61% |
| 2015 Q1 | 764.92 Million SEK | -5.7% |
| 2014 Q1 | 721.54 Million SEK | 0.6% |
| 2014 FY | 811.12 Million SEK | 13.09% |
| 2014 Q4 | 811.12 Million SEK | -5.67% |
| 2014 Q3 | 859.84 Million SEK | -8.97% |
| 2014 Q2 | 944.6 Million SEK | 30.91% |
| 2013 Q3 | 699.88 Million SEK | -1.06% |
| 2013 Q4 | 717.23 Million SEK | 2.48% |
| 2013 FY | 717.23 Million SEK | 1.93% |
| 2013 Q1 | 704.7 Million SEK | 0.15% |
| 2013 Q2 | 707.39 Million SEK | 0.38% |
| 2012 Q3 | 740.96 Million SEK | -0.86% |
| 2012 Q2 | 747.42 Million SEK | 0.0% |
| 2012 FY | 703.63 Million SEK | 8.13% |
| 2012 Q4 | 703.63 Million SEK | -5.04% |
| 2011 Q4 | 650.73 Million SEK | 0.0% |
| 2011 FY | 650.73 Million SEK | 20.54% |
| 2010 FY | 539.84 Million SEK | -12.84% |
| 2009 FY | 619.35 Million SEK | -10.27% |
| 2008 FY | 690.26 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Acarix AB (publ) | 62.88 Million SEK | -985.933% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 79.227% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 79.227% |
| Arcoma AB | 81.96 Million SEK | -733.164% |
| BICO Group AB (publ) | 10.19 Billion SEK | 93.303% |
| Boule Diagnostics AB (publ) | 755.1 Million SEK | 9.565% |
| CellaVision AB (publ) | 928.71 Million SEK | 26.47% |
| Clinical Laserthermia Systems AB (publ) | 57.72 Million SEK | -1082.985% |
| Chordate Medical Holding AB (publ) | 21.95 Million SEK | -3010.285% |
| C-Rad AB (publ) | 404 Million SEK | -69.029% |
| Duearity AB (publ) | 15.14 Million SEK | -4409.231% |
| Dignitana AB (publ) | 44.83 Million SEK | -1423.227% |
| Episurf Medical AB (publ) | 104.3 Million SEK | -554.725% |
| Getinge AB (publ) | 55.09 Billion SEK | 98.761% |
| Scandinavian Real Heart AB (Publ) | 102.63 Million SEK | -565.325% |
| Iconovo AB (publ) | 128.07 Million SEK | -433.166% |
| Integrum AB (publ) | 164.85 Million SEK | -314.219% |
| Luxbright AB (publ) | 40.68 Million SEK | -1578.383% |
| Mentice AB (publ) | 322.52 Million SEK | -111.728% |
| OssDsign AB (publ) | 356.38 Million SEK | -91.61% |
| Paxman AB (publ) | 167.12 Million SEK | -308.603% |
| Promimic AB (publ) | 92.87 Million SEK | -635.266% |
| Qlife Holding AB (publ) | 39.04 Million SEK | -1648.906% |
| SciBase Holding AB (publ) | 64.33 Million SEK | -961.457% |
| ScandiDos AB (publ) | 81.47 Million SEK | -738.165% |
| Sectra AB (publ) | 3.21 Billion SEK | 78.733% |
| Sedana Medical AB (publ) | 1.01 Billion SEK | 32.659% |
| Senzime AB (publ) | 433.54 Million SEK | -57.511% |
| SpectraCure AB (publ) | 144.83 Million SEK | -371.49% |
| Stille AB | 804.89 Million SEK | 15.159% |
| Vitrolife AB (publ) | 16.39 Billion SEK | 95.834% |
| Xvivo Perfusion AB (publ) | 2.19 Billion SEK | 68.898% |